Mechanistically, CCL5 binds to the CCR5 receptor on tumor cell surfaces, activating the downstream AKT signaling pathway, which cooperatively promotes AR and PD-L1 upregulation, ultimately driving CRPC progression and therapy resistance. The gene discussed is AR; the disease is neoplasm.